Can romiplostim be discontinued after long-term use?

Romiplostim is a thrombopoietin receptor agonist, mainly used to treat patients with chronic immune thrombocytopenia (ITP), especially adults who have failed to respond to glucocorticoid or immunoglobulin therapy. It increases the patient's platelet count by stimulating the maturation of megakaryocytes and platelet production in the bone marrow. Because its mechanism does not act directly on the immune system but rather relieves symptoms by enhancing platelet production, many patients require long-term maintenance therapy to maintain stable platelet levels.

Whether romigrastim can be discontinued depends on the patient's individual response and disease control. After some patients with ITP have been treated with romiplostim for a period of time, their platelet count remains stable without obvious bleeding symptoms. They may gradually reduce the dose or even discontinue the drug after a doctor's evaluation. However, it must be emphasized that such patients who "successfully discontinue medication" are in the minority, and most people still need to continue taking medication to maintain platelets within a safe range. Once the drug is stopped blindly, it may cause platelets to drop rapidly and increase the risk of serious bleeding.

Long-term use of romigrastim is well tolerated in most patients and has few side effects, but regular monitoring is required. Some patients may develop bone marrow fibrosis, thrombophilia and other problems. Therefore, during long-term treatment, regular checks of blood, liver and kidney function, and bone marrow status are required. Doctors will decide whether to try to reduce or discontinue the drug based on the patient's overall health, risk of complications, and platelet fluctuations. Some studies have shown that if the patient maintains a long-term remission state during treatment (such as platelet count >50×10⁹/L for more than 12 months), gradual discontinuation of the drug for observation may be considered.

In short, whether romiplostim can be discontinued depends on the individual condition and cannot be generalized. For patients who are willing to discontinue the drug, the dose should be reduced slowly under the close supervision and guidance of a doctor, and changes in platelet levels should be continuously monitored. Do not stop taking the medicine on your own to avoid serious consequences. Long-term users should maintain regular review to ensure stable efficacy and safety, and handle any side effects in a timely manner. The goal of treatment should be to be safe, effective, individualized, and ultimately improve the patient's quality of life.

Reference: https://en.wikipedia.org/wiki/Romiplostim